RAPT THERAPEUTICS ($RAPT) posted quarterly earnings results on Thursday, March 6th. The company reported earnings of -$1.14 per share, missing estimates of -$0.38 by $0.76. The company also reported revenue of $0, equaling estimates of $0 by $0.
You can see Quiver Quantitative's $RAPT stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
RAPT THERAPEUTICS Hedge Fund Activity
We have seen 53 institutional investors add shares of RAPT THERAPEUTICS stock to their portfolio, and 67 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- MEDICXI VENTURES MANAGEMENT (JERSEY) LTD added 22,352,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $35,316,160
- ORBIMED ADVISORS LLC added 13,135,260 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,753,710
- TCG CROSSOVER MANAGEMENT, LLC added 13,135,260 shares (+inf%) to their portfolio in Q4 2024, for an estimated $20,753,710
- RTW INVESTMENTS, LP added 11,764,000 shares (+inf%) to their portfolio in Q4 2024, for an estimated $18,587,120
- BVF INC/IL added 9,237,556 shares (+inf%) to their portfolio in Q4 2024, for an estimated $14,595,338
- DEEP TRACK CAPITAL, LP added 6,011,380 shares (+inf%) to their portfolio in Q4 2024, for an estimated $9,497,980
- REDMILE GROUP, LLC added 5,970,785 shares (+1183.4%) to their portfolio in Q4 2024, for an estimated $9,433,840
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
